Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics

Pediatr Blood Cancer. 2020 Dec;67(12):e28516. doi: 10.1002/pbc.28516. Epub 2020 Jun 23.

Authors

Christopher Kuo¹, Dione Foon², Kaaren Waters², Clement Cheung^{3

4}, Ashley S Margol^{2

4}

Affiliations

¹ Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California.
² Cancer and Blood Disease Institute and Division of Hematology Oncology, Children's Hospital Los Angeles, Los Angeles, California.
³ Division of Endocrinology, Diabetes, and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California.
⁴ Keck School of Medicine, University of Southern California, Los Angeles, California.

PMID: 32573959
DOI: 10.1002/pbc.28516

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Alkylating / adverse effects*
Brain Neoplasms / drug therapy*
Brain Neoplasms / pathology
Child
Diabetes Insipidus, Neurogenic / chemically induced
Diabetes Insipidus, Neurogenic / pathology*
Humans
Male
Neoplasms, Neuroepithelial / drug therapy*
Neoplasms, Neuroepithelial / pathology
Prognosis
Rare Diseases / chemically induced
Rare Diseases / pathology*
Temozolomide / adverse effects*

Substances

Antineoplastic Agents, Alkylating
Temozolomide